the firm's post-grant practitioners are some of the most experienced in the country.

Sameer  Gokhale
Kurt M. Berger, Ph.D.
Christopher I. Donahue
Robert T. Pous
Richard D. Kelly
Alec M. Royka
Philippe J.C. Signore, Ph.D.
Derek  Lightner, Ph.D.
Craig R. Feinberg
Edwin D. Garlepp
John  Sipos
J. Derek  Mason, Ph.D., CLP
Norman F. Oblon
Michael R. Casey, Ph.D.
Grace E. Kim
Brian B. Darville
Chika (Teranishi) Iitoyo
David M. Longo, Ph.D.
Carl E. Schlier
Elissa L. Sanford
Andrew M. Ollis
John S. Kern
Kevin Ross  Davis
Tao  Feng, Ph.D.
Jeffrey B. McIntyre
Daniel J. Pereira, Ph.D.
John F. Presper
Kevin M. McKinley
Dale M. Shaw
Jenchieh (Joseph) Yuan
Steven B. Chang
Marina I. Miller, Ph.D.
Charles L. Gholz
Stefan Uwe  Koschmieder, Ph.D.
Arthur I. Neustadt
Akihiro  Yamazaki
Stephen G. Baxter, Ph.D.
Bogdan A. Zinchenko
Tia D. Fenton
Diane  Jones
Alexander B. Englehart
Eckhard H. Kuesters
Jay E. Rowe, Jr., Ph.D.
Kevin L. Hartman, Ph.D.
Kasumi  Kanetaka
Long  Phan, Ph.D.
Thomas M. Cunningham, Ph.D.
Surinder  Sachar
Yuki  Onoe
Teddy S. Gron
Colin B. Harris
Ryan W. Smith
Nicholas  Rosa, Ph.D.
Aldo  Martinez
Frank J. West
Jianping (James)  Wu
Robert  Tarcu
Yorikatsu  Hohokabe, Ph.D.
James R. Love
Robert W. Downs
Christopher  Ricciuti
Yuanyi (Alex) Zhang, Ph.D.
Eric W. Schweibenz


Artificial Intelligence (AI)
Artificial Intelligence (AI)
Digital Health
Digital Health
Energy & Renewables
Energy & Renewables

Fast Facts

About Our

Law Firm

About Our Law Firm

Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.

Get to know our


Get to know our History

Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.

Our Local and

Global Reach

Our Local and Global Reach

Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.

A few of our


A few of our ACCOLADES

Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.




From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.

A few ways to

GET In Touch

A few ways to GET In Touch
US Office

Telephone: 703-413-3000
Learn More +

Tokyo Office

Telephone: +81-3-6212-0550
Learn More +


Patent Forms

Downloadable Patent Forms

The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.

USPTO Announces COVID-19 Deferred-Fee Provisional Patent Application Pilot Program

  • September 16, 2020
  • Firm News

On Wednesday, September 16, 2020, the USPTO issued a release stating:

The United States Patent and Trademark Office (USPTO) today announced a collaborative deferred-fee provisional patent application pilot program for inventions that combat COVID-19.  

The USPTO recognizes that its mission to issue high-quality patents to inventors goes hand-in-hand with dissemination of important scientific information to the public to promote further innovation. This information flow is now more important than ever in view of the urgent challenges posed by the COVID-19 outbreak. Under the pilot program, applicants may defer payment of the provisional application filing fee until the filing of a corresponding, non-provisional application. To foster dissemination and collaboration, they must agree that the technical subject matter disclosed in their provisional applications will be available to the public on the USPTO’s website. By making their disclosures available, applicants can contribute to the public in the fight against COVID-19 while protecting their patent rights. 

To qualify for the program, the subject matter disclosed in the provisional application must concern a product or process related to COVID-19, and such product or process must require Food and Drug Administration (FDA) approval for COVID-19 use, whether such approval has been obtained, is pending, or will be sought prior to marketing the subject matter for COVID-19.

The program is scheduled to accept applications for 12 months beginning on September 17, 2020. For more information on the deferred-fee provisional patent application pilot program, please read the full notice.

Relatedly, and further to our April 28, 2020 post, Oblon is proud to still be currently waiving our fee for filing a provisional application for an invention directly related to addressing the COVID-19 pandemic.

Please contact us if you have any questions regarding this item.